Cargando…
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
BACKGROUND: Randomized controlled trials (RCT) generalizability may be limited due to strict patient selection. OBJECTIVE: In a real‐world heart failure (HF) population, we assessed eligibility for sacubitril/valsartan based on PARADIGM‐HF (sacubitril/valsartan effective)/PARAGON‐HF [sacubitril/vals...
Autores principales: | Savarese, G., Hage, C., Benson, L., Schrage, B., Thorvaldsen, T., Lundberg, A., Fudim, M., Linde, C., Dahlström, U., Rosano, G. M. C., Lund, L. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984286/ https://www.ncbi.nlm.nih.gov/pubmed/32776357 http://dx.doi.org/10.1111/joim.13165 |
Ejemplares similares
-
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021) -
“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019) -
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020) -
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022) -
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)